Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose more than 7% Kailimei® passed the preliminary review of the 2026 Commercial Insurance Innovative Drug Catalogue

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose more than 7%. As of press release, it had risen 6.7% to HK$17.05, with a turnover of HK$46.3934 million.

According to the news, on July 16, Keji Pharmaceutical announced that according to the announcement of the National Health Insurance Administration, Kalimei® (Schuriziolenol injection, product number: CT041, an autologous CAR-T cell therapy candidate product targeting Claudin18.2) has successfully passed the 2026 National Commercial Health Insurance Innovative Drug Catalogue Adjustment Preliminary Form Review. As the world's first CAR-T therapy for solid tumors approved for marketing, this product achieved a historic leap forward in cellular immunotherapy from hematoma to solid tumor, and accurately filled the clinical gap in advanced gastric cancer treatment.